COVID-19 Antigen Rapid Test
Rapid detection of SARS-CoV-2 antigen to support point-of-care screening.
- Target
- SARS-CoV-2 nucleocapsid antigen
- Specimen
- Nasal / nasopharyngeal swab
- Result in
- 15 min
- Setting
- Point-of-care, clinics, workplaces
ImmediKits is bringing a focused portfolio of Class II, III and IV rapid diagnostic test kits to Canada and the wider North American market — fast, reliable point-of-care testing for clinics, pharmacies, hospitals and public-health programs.
Medical Device Licence applications are in process. Products are not yet available for sale.
Pregnancy, fertility and drug-screening tests
Respiratory, strep, cardiac, oncology-marker and STI tests
HIV and hepatitis B / C screening tests
ImmediKits is a new rapid-diagnostics brand entering the Canadian and North American market with a single, clear focus: point-of-care rapid test kits. We work with established international manufacturers to bring proven test formats — cassettes, strips, panels and combo tests — to the healthcare providers who need answers in minutes, not days.
We are building licence-first. Our Medical Device Licence (MDL) applications have been submitted to Health Canada, and every kit on this site will remain “coming soon” until it is licensed. In the meantime we are building our distributor network across Canada and North America so that partners are ready on launch day.
Our name says it: Immediate results, from Kits that are simple to run, easy to stock and backed by transparent documentation.
Rapid formats that deliver results at the point of care, typically in 5–20 minutes.
MDL applications submitted. We sell nothing in Canada until each kit is licensed.
Only rapid test kits — across infectious disease, cardiac, endocrine, toxicology and more.
Launching in Canada with a distributor network planned across North America.
Health Canada classifies in-vitro diagnostic devices by risk. ImmediKits covers the full range used in rapid point-of-care testing.
Everyday screening tests used in clinics, pharmacies and at home.
Tests that guide time-sensitive clinical decisions.
Screening for serious blood-borne infections.
Classes shown are anticipated and subject to Health Canada’s determination.
A preview of the kits in our MDL pipeline. All listings are “coming soon” and are not available for sale.
Rapid detection of SARS-CoV-2 antigen to support point-of-care screening.
Rapid detection of Group A strep antigen to support pharyngitis assessment.
Qualitative detection of cardiac troponin I to support rapid cardiac assessment.
Rapid detection of antibodies to HIV-1 and HIV-2 for point-of-care screening.
Qualitative detection of hCG for early confirmation of pregnancy.
Screens for multiple drug classes at once, in configurable 5- to 12-panel formats.
Tell us about your company, territory and the customers you serve.
We review fit, coverage and capabilities, then schedule an introductory call.
Receive product documentation and plan launch volumes for your territory.
Begin supplying as each kit’s Medical Device Licence is issued.
We are building our distribution network across Canada and North America ahead of launch. Medical distributors, pharmacy wholesalers, lab suppliers and group purchasing partners are invited to apply.